Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Part I (Survey/Information stage):
- People who are 45 years of age or older
- People who are female or were assigned female at birth
- People who have a scheduled appointment with a non-gynaecological surgeon
Part II (Procedure stage):
- People who are 45 years of age or older
- People who have at least one fallopian tube still in place
- People who do not want or plan to have children in the future
- People who are considered to have an average risk of developing ovarian cancer — meaning no known genetic risk factors for ovarian cancer (if a family history suggests a possible hereditary risk but no genetic testing has been done, the trial site would refer that person for genetic evaluation first)
- People who are already scheduled for a non-gynaecological surgery inside the abdomen or pelvis
- People considered a suitable candidate by both a gynaecological surgeon and their primary (non-gynaecological) surgeon
- People who have read, agreed to, and signed the trial consent form
Who may not be able to join:
Part I:
- People who are not fluent in English or Spanish (note: people who are not fluent in English or Spanish but meet all other criteria may still be eligible to enter Part II directly — confirm with the trial site)
- People with a known inherited susceptibility to ovarian cancer
Part II:
- People with a personal history of a gynaecological cancer
- People who carry a gene variant linked to hereditary breast or ovarian cancer risk (for example, BRCA1, BRCA2, or similar variants)
- People whose pre-surgery scans showed a suspicious growth on the ovaries, fallopian tubes, or uterus
- People who have previously had both fallopian tubes removed, or both fallopian tubes and ovaries removed
- People who have an ESSURE device or any other implanted tubal contraceptive device in place at the time of surgery
- People who are currently pregnant
- People whose surgery is an emergency procedure that must be completed within 24 hours, or where their health is in immediate danger
- People whose primary surgeon expects that adding this procedure would significantly extend the operation time (more than 30–40 minutes)
- People whose planned surgery position (for example, lying face-down or on their side) would prevent the surgeon from accessing the pelvic area
- People with a known history of pelvic scarring or significant internal adhesions (bands of scar tissue)
- People whose planned surgery is intended for comfort or symptom management only (palliative intent), rather than treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kara Long Roche, MD, Memorial Sloan Kettering Cancer Center
Phone: 212-639-7043
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of Opportunistic Salpingectomy/OS after completion of educational module
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.